biopharma-catalyst-mcp
Server Configuration
Describes the environment variables required to run the server.
| Name | Required | Description | Default |
|---|---|---|---|
| SEC_USER_AGENT | Yes | Your contact email for SEC EDGAR compliance. Required to avoid rate limiting. |
Instructions
Guidance the server publishes about itself, which clients place ahead of the tool catalog so the model reads it before choosing anything.
This server publishes no instructions, or was last inspected before Glama recorded them.
Capabilities
Features and capabilities supported by this server
Protocol revision2025-11-25
| Capability | Details |
|---|---|
| tools | {} |
Tools
Functions exposed to the LLM to take actions
| Name | Description |
|---|---|
| search_clinical_trialsB | Search ClinicalTrials.gov for studies by intervention (drug or company name) |
| search_pubmedA | Search PubMed for scientific papers by term (drug name, condition, etc.) |
| get_sec_filingsC | Get recent SEC filings (10-K, 10-Q, 8-K, S-1) for a stock ticker. |
| get_market_dataB | Get current price and options data for a stock ticker |
| get_fda_activityA | Get FDA submission and approval activity for a drug or sponsor (NDA/BLA filings, approvals, supplements). Use kind='drug' for drug name (brand or generic) or kind='sponsor' for company sponsor name. Submission status codes are decoded (AP=approved, CRL=rejection, WD=withdrawn). Supports auto-fallback from drug to sponsor if results are empty. |
| get_xbrl_factsA | Get structured financial facts from SEC XBRL for a ticker — cash, quarterly burn, runway months, and Going Concern disclosure flag. Used by the Tactical Auditor to detect dilution risk (runway shorter than time to next catalyst). |
| get_insider_transactionsA | Get insider Form 4 transactions for a ticker over the last N days. Returns individual transactions, total sales/purchases in dollars, and a Net Insider Sentiment score (purchases - sales). Detects 10b5-1 scheduled sales but does not exempt them. |
| get_protocol_snapshotA | Get current protocol details + amendment proximity for a clinical trial by NCT ID. Flags late-stage protocol amendments (the 'goalpost move') by computing how far into the trial timeline the last update happened. Cannot detect WHAT changed (CT.gov v2 API does not expose protocol diffs) — only WHEN. |
| audit_catalystA | FORENSIC AGGREGATOR. Runs all 8 connectors in parallel against (ticker, drug) and returns a deterministic verdict: CLEAN | FLAG | BEAR_SIGNAL | BLACK_FLAG. Encodes the full Tactical Auditor logic — terminations, FDA rejections, late-stage protocol amendments, dilution risk (runway vs catalyst), Going Concern disclosure, insider unloading, 8-K clusters, literature skepticism. CLEAN means: tried to break the thesis, couldn't. The strongest long signal this tool gives. |
| get_short_interestA | Get short interest data for a ticker — short % of float, days to cover, and month-over-month delta. Used to detect SHORT_INTEREST_SPIKE (delta >20%, bear) and SHORT_SQUEEZE_POTENTIAL (days to cover >5, bull). |
Prompts
Interactive templates invoked by user choice
| Name | Description |
|---|---|
No prompts | |
Resources
Contextual data attached and managed by the client
| Name | Description |
|---|---|
No resources | |
TDQS
Scored across 10 tools
Each tool targets a distinct aspect of biopharma analysis—FDA activity, clinical trials, insider transactions, SEC filings, market data, short interest, XBRL facts, PubMed literature, and a high-level aggregator. There is no overlap; even the audit_catalyst synthesizes data from others rather than duplicating.
Tool names follow a consistent verb_noun pattern with underscores: 'get_*' for data retrieval, 'search_*' for database queries, and 'audit_catalyst' for the aggregator. The verb choice accurately reflects the action type, and all names are clear and predictable.
Ten tools is within the ideal 3-15 range for a domain-specific MCP server. Each tool covers a necessary data source or analytical function, and none feel redundant or extraneous.
The tool set covers the full lifecycle of biopharma catalyst analysis: FDA actions, clinical trials, insider trading, financials (XBRL and SEC filings), short interest, market data, and literature. The audit_catalyst aggregates these into a verdict, leaving no obvious gaps for the stated purpose.